Skip to main content

Rare Diseases

New FDA Approved for Polymyalgia Rheumatica - Secukinumab

Jack Cush, MD

Today the US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. This is the first anti-IL-17 biologic approved for

anita
@docdhanrajani
@RheumNow My top 5 from #ACR2026. #5. Abstract 2484. Addressing unmet needs in cSLE using #CARRA registry data. cSLE patients have significant burden of unmet therapeutic needs with currently approved therapies. Urgent call to expedite regulatory approvals of cSLE therapies!
Janet Pope
@Janetbirdope
#FcRn #efigartigimod + #RCT in #IMNM & #DM #LB24 But 😞 #SjD RCT stopped 🛑 for #futility We will have niche Rx for many rare #SARDs I think over next few yrs #ACR26 @ACRheum @RheumNow

ACR 2026 Day 3 Report

Jack Cush, MD

Today the ACR began with the Great Debate, an intriguing set of Plenary presentations, a never-ending poster hall and a plethora of stimulation oral presentation sessions. Here are a few of my favorites from today:

Mike Putman
@EBRheum
Worse outcomes among young pts who develop anti-HMGCR myopathy Hopkins cohort of 218 pts, statin naive pts more often younger (38.2 vs 59.8 years statin exposed) In multivariable analysis, younger age independently predicted worse long term outcomes This makes sense to me from
Audrey Gibson
@Gibson_RheumPAC
What if we could identify SLE BEFORE clinical disease develops? New longitudinal proteomic research reveals distinct molecular trajectories preceding SLE progression. Could a future blood test help distinguish pts at risk from those who may never develop lupus? #1821 @RheumNow
Daric Mueller, PA-C
@rheumPAC
Mortality in IIM-ILD: frontloaded but survival + improvement possible! 2 year mortality outcomes in a newly diagnosed IIM-cohort (n=41), 15% died @ median time of 8.5 months. Of survivors, only 13.3% progressed, 46.7% improved as measured by % pred FVC. #ACR26 @Rheumnow
Richard Conway
@RichardPAConway
Terrier et al. RCT Mepolizumab vs conventional therapy for induction in EGPA. No sig diff day 168 remission (61% vs 51%). Did significantly increase sustained remission, glucocorticoid-free remission and EGPA-related event-free survival at day 364 @RheumNow #ACR26 Abst#0926
Mike Putman
@EBRheum
High risk of recurrence for pulmonary artery thrombosis in Behcet Retrospective cohort of 137 pts w/Behcets observed relapse rateof 26% (compared to 30% for non-BD thrombi) Makes sense; Behcets is a less-modifiable risk factor & the inflammatory vasculopathy can be hard to
Adela Castro
@AdelaCastro222
What is new in IgG4? Obexelimab: significant efficacy compared to placebo with no major safety signals. -Non B cell depletion -Rapid B cell recovery -Long-term safety advantage of not depleting B cells yet not available. -Benefit in fibrotic, multisystem or refractory disease is https://t.co/whNiZwDSjI

3 x IL-23 = IL do Better (11.6.2026)

Jack Cush, MD

Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA. 

×